The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova T.M.

Sechenov First Moscow State Medical University (Sechenov University)

Ostroumova O.D.

Russian Medical Academy for Continuous Professional Education

Knock down the scope. The brain as a target organ for arterial hypertension

Authors:

Ostroumova T.M., Ostroumova O.D.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2023;(10‑11): 62‑72

Read: 762 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Ostroumova TM, Ostroumova OD. Knock down the scope. The brain as a target organ for arterial hypertension. Non Nocere. New Therapeutic Journal. 2023;(10‑11):62‑72. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Relationship between arterial hypertension and cognitive impairment.

Authors:

Ostroumova T.M.

Sechenov First Moscow State Medical University (Sechenov University)

Ostroumova O.D.

Russian Medical Academy for Continuous Professional Education

Close metadata

References:

  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980. https://doi.org/10.1016/S0140-6736(21)01330-1
  2. Erina A.M., Rotar O.P., Solntsev V.N., Shalnova S.A., Deev A.D., Baranova E.I., Konradi O.A., Boytsov S.A., Shlyakhto E.V. Epidemiology of Arterial Hypertension in Russian Federation – Importance of Choice of Criteria of Diagnosis. Kardiologiia. 2019;59(6):5-11. (In Russ.) https://doi.org/10.18087/cardio.2019.6.2595
  3. Kobolava Zh.D., Konradi A.O., Nedogoda S. V., at al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786
  4. Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 Jun 21. https://doi.org/10.1097/HJH.0000000000003480
  5. Ministry of Health of the Russian Federation. Clinical Recommendations “Cognitive disorders in elderly and senile persons”. https://cr.minzdrav.gov.ru/recomend/617_1
  6. Levine DA, Springer MV, Brodtmann A. Blood Pressure and Vascular Cognitive Impairment. Stroke. 2022;53(4):1104-1113. https://doi.org/10.1161/STROKEAHA.121.036140
  7. Sáiz-Vazquez O, Puente-Martínez A, Pacheco-Bonrostro J, Ubillos-Landa S. Blood pressure and Alzheimer’s disease: A review of meta-analysis. Front Neurol. 2023;13:1065335. https://doi.org/10.3389/fneur.2022.1065335
  8. GBD2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. https://doi.org/10.1016/S2468-2667(21)00249-8
  9. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000 Jan-Feb;21(1):49-55. https://doi.org/10.1016/s0197-4580(00)00096-8
  10. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005 Jan 25;64(2):277-281. https://doi.org/10.1212/01.WNL.0000149519.47454.F2
  11. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001 Jun 16;322(7300):1447-1451. https://doi.org/10.1136/bmj.322.7300.1447
  12. Gottesman RF, Schneider ALC, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife hypertention and 20-year cognitive change. JAMA Neurol. (2014) 21287:1-10. https://doi.org/10.1001/jamaneurol.2014.1646
  13. Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife Hypertension and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2019;71(1):307-316. https://doi.org/10.3233/JAD-190474
  14. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996 Apr 27;347(9009):1141-1145. https://doi.org/10.1016/s0140-6736(96)90608-x
  15. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003 Feb;60(2):223-228. https://doi.org/10.1001/archneur.60.2.223
  16. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161-1168. https://doi.org/10.1212/wnl.45.6.1161
  17. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002 Apr;58(8):1175-1181. https://doi.org/10.1212/wnl.58.8.1175
  18. Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003;60(10):1394-1399. https://doi.org/10.1001/archneur.60.10.1394
  19. Levine DA, Springer MV, Brodtmann A. Blood Pressure and Vascular Cognitive Impairment. Stroke. 2022 Apr;53(4):1104-1113. https://doi.org/10.1161/STROKEAHA.121.036140
  20. Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: A longitudinal study from the Kungsholmen project. Stroke. 2004;35:1810-1815.
  21. Walker KA, Sharrett AR, Wu A, Schneider ALC, Albert M, Lutsey PL, et al. Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. JAMA. 2019 Aug 13;322(6):535-545. https://doi.org/10.1001/jama.2019.10575
  22. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, Csiszar A. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021 Oct;17(10):639-654. https://doi.org/10.1038/s41581-021-00430-6
  23. Kelly D.M., Rothwell P.M.M. Blood pressure and the brain: The neurology of hypertension. Pract. Neurol. 2020;20:100-111. https://doi.org/10.1136/practneurol-2019-002269
  24. Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension. Circ Res. 2019 Mar 29;124(7):1025-1044. https://doi.org/10.1161/CIRCRESAHA.118.313260
  25. Ungvari Z, Tarantini S, Nyúl-Tóth Á, Kiss T, Yabluchanskiy A, Csipo T, et al. Nrf2 dysfunction and impaired cellular resilience to oxidative stressors in the aged vasculature: from increased cellular senescence to the pathogenesis of age-related vascular diseases. Geroscience. 2019 Dec;41(6):727-738. https://doi.org/10.1007/s11357-019-00107-w
  26. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative Stress and Hypertension. Circ Res. 2021 Apr 2;128(7):993-1020. https://doi.org/10.1161/CIRCRESAHA.121.318063
  27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing. 2013;87-122. https://archive.org/details/american-psychiatric-association-diagnostic-and-statistical-manual-of-mental-dis/page/n9/mode/2up
  28. Alateeq K, Walsh EI, Cherbuin N. Higher Blood Pressure is Associated with Greater White Matter Lesions and Brain Atrophy: A Systematic Review with Meta-Analysis. J Clin Med. 2021 Feb 7;10(4):637. https://doi.org/10.3390/jcm10040637
  29. Li Z, Wang W, Sang F, Zhang Z, Li X. White matter changes underlie hypertension-related cognitive decline in older adults. Neuroimage Clin. 2023;38:103389. https://doi.org/10.1016/j.nicl.2023.103389
  30. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014 Jul 9;12:119. https://doi.org/10.1186/s12916-014-0119-0
  31. Ungvari Z, Tarantini S, Kirkpatrick AC, Csiszar A, Prodan CI. Cerebral microhemorrhages: mechanisms, consequences, and prevention. Am J Physiol Heart Circ Physiol. 2017 Jun 1;312(6): H1128–H1143. https://doi.org/10.1152/ajpheart.00780.2016
  32. Toth P, Tarantini S, Springo Z, Tucsek Z, Gautam T, Giles CB, et al. Aging exacerbates hypertension-induced cerebral microhemorrhages in mice: role of resveratrol treatment in vasoprotection. Aging Cell. 2015;14(3):400-408. https://doi.org/10.1111/acel.12315
  33. Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12 (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
  34. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(12):86-90. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2012/12/031997-729820121215
  35. Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(5):64-68. (In Russ.) https://doi.org/10.17116/jnevro20181185164
  36. Ekusheva EV, Biryukova EV. The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(12):138-143. (In Russ.) https://doi.org/10.17116/jnevro2020120121138
  37. Burdakov VV, Krasnykh DV. The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):56-60. (In Russ.) https://doi.org/10.14412/2074-2711-2020-1-56-60
  38. Zhuravleva MV, Prokofiev AB, Serebrova SYu, Vasyukova NS, Demchenkova EYu, Arkhipov VV. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(6):119-124. (In Russ.) https://doi.org/10.17116/jnevro2020120061119
  39. Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, Ostroumova TM, Ostroumova OD. Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(8-2):49-57. (In Russ.) https://doi.org/10.17116/jnevro202012008249
  40. Fedin AI, Zaharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11):7-16. (In Russ.) https://doi.org/10.17116/jnevro20211211117
  41. Portal of public discussion of draft clinical recommendations [Electronic resource]. Statement №888. Clinical recommendations “Cognitive disorders in elderly and senile persons”. Date of circulation: 12.09.2023. https://portalcr.minzdrav.gov.ru/viewCR/1273
  42. Zakharov V.V., Ostroumova O.D., Kochetkov A.I., et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159. (In Russ.) https://doi.org/10.18565/therapy.2023.1.145-159
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.